A Phase 1b Study of CLN-049 in Combination With Azacitidine and Venetoclax in AML Patients

NCT07722767 · clinicaltrials.gov ↗

PHASE1

Phase

NOT_YET_RECRUITING

Status

90

Enrollment

INDUSTRY

Sponsor class

Conditions

AML (Acute Myeloid Leukemia)

Interventions

DRUG: CLN-049
DRUG: Azacitidine
DRUG: Venetoclax

Sponsor

Cullinan Therapeutics Inc.